Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, such as gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback ankle fusion plating systems. The company also provides precision guide technology for various procedures consisting of MTP fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot; bunion or hallux valgus correction systems; phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics, such as bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Further, the company provides hammertoe implants, titanium wedges, and soft tissue fixators, as well as products for the various procedure, such as bunions, flatfoot, fracture fixation, and foot fracture. It serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was incorporated in 2010 and is headquartered in Englewood, Colorado.
IPO Year: 2021
Exchange: NYSE
Website: paragon28.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/29/2023 | Outperform | William Blair | |
| 4/11/2023 | $23.00 | Overweight | Stephens |
| 12/14/2022 | $32.00 | Buy | B. Riley Securities |
| 3/9/2022 | $30.00 → $25.00 | Buy | B of A Securities |
| 3/9/2022 | $25.00 → $23.00 | Buy | Canaccord Genuity |
| 2/9/2022 | $31.00 → $25.00 | Buy | Needham |
| 11/9/2021 | $30.00 | Market Outperform | JMP Securities |
| 11/9/2021 | $28.00 | Buy | Canaccord Genuity |
| 11/9/2021 | $30.00 | Overweight | Piper Sandler |
| 11/9/2021 | $31.00 | Buy | Needham |
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
3 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
4 - Paragon 28, Inc. (0001531978) (Issuer)
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "P28"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024. Preliminary unaudited net revenue for the fourth quarter of 2024 is expected to be in a range of $71.5 to $71.8 million, representing reported growth of approximately 18.0% to 18.5% compared to the fourth quarter of 2023. Preliminary unaudited net revenue for the full year of 2024 is expected to be in a range of $255.9 to $256.2 million, representing reported growth of approximately 18.2% to 18.4%, compared to the ful
Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Chadi Chahine, CFO & EVP of Supply Chain Operations, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. Pacific Time / 8:30 a.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section of the Company's website at ir.paragon28.com. About Paragon 28, Inc. Based in Englewood, CO., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is
Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi
Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Chadi Chahine, CFO, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section of the Company's website at ir.paragon28.com. About Paragon 28, Inc. Based in Englewood, Colo., Paragon 28 is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedi
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a
Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The
Paragon 28, Inc. (NYSE:FNA) is pleased to announce the launch of the Phantom® Fibula Nail System, designed to give surgeons a less invasive option to treat the fibula when patients sustain an ankle fracture. Use of a fibula nail for the treatment of ankle fractures has been shown to have significantly fewer soft tissue complications, implant removals, and fracture nonunion when compared to plate and screw fixation, a common alternative approach.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241016226468/en/Figure 1: Phantom® Fibula Nail implanted in the fibula for fracture stabilization with syndesmotic repair using the R3FLEX™
Paragon 28, Inc. (NYSE:FNA) is pleased to announce the addition of a novel Right-Angle Drill to the APEX 3D™ Total Ankle Replacement System designed to improve tibia preparation prior to the implantation of the APEX 3D™ tibia implant. The Right-Angle Drill utilizes a linear guide to precisely drill vertical holes into the tibia for ideal peg placement and a highly stable tibia implant interface. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910193295/en/Figure 1: Image of the APEX 3D Right-Angle Drill as a standalone unit. (Graphic: Business Wire) The release of the Right-Angle Drill continues a series of instrumentation enha
Paragon 28, Inc. (NYSE:FNA), is pleased to announce the launch of the R3FLEX™ Stabilization System, which is designed to restore stability to the ankle syndesmosis after injury from an ankle fracture or high ankle sprain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904839497/en/Figure 1: R3FLEX™ Stabilization System and Gorilla® Ankle Fracture Plating System used to treat an ankle fracture with syndesmotic injury. (Graphic: Business Wire) Ankle fractures are one of the most common injuries with over 470,000 predicted in 2024 in the US.1,2 Injury to the distal tibiofibular syndesmosis is estimated to occur in 23% of ankle f
Paragon 28, Inc. (NYSE:FNA), is proud to announce the launch of the SMART28℠ Case Management Portal, a cutting-edge platform that leverages AI and a seamless user experience to coordinate patient-specific surgical plans. It is the first major launch of Paragon 28's SMART28℠ ecosystem, a portfolio of solutions and products that drive Paragon 28's SMART28℠ initiative: to improve all aspects of foot and ankle treatments through the utilization of artificial intelligence, data analytics, patient specific algorithms, 3D modeling, and other enabling technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240814610485/en/Figure 1:
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a
Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Chadi Chahine has been appointed Chief Financial Officer and Executive Vice-President of Supply Chain Operations, effective August 5, 2024. The Company also reported financial results for the quarter ended June 30, 2024, and narrowed its 2024 net revenue guidance. Recent Business Updates Strengthened executive leadership team with appointment of Chadi Chahine as CFO & EVP Supply Chain Operations, effective August 5, 2024 Recorded global revenue of $61.0 million in the second quarter, representing 19.6% and 19.7% r
Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2024 after market close on Thursday, August 8, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 389675. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2024, and reaffirmed its 2024 net revenue guidance. First Quarter 2024 Financial Results Consolidated net revenue for the first quarter of 2024 was a record $61.1 million, representing 17.4% reported and constant currency growth over the first quarter of 2023. Foreign currency impact on first quarter 2024 reported net revenue growth was not material. U.S. net revenue for the first quarter of 2024 was $51.1 million, representing growth of 13.5% over the first quarter of 20
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2023 and provided 2024 Net Revenue guidance. Fourth Quarter and Full Year 2023 Financial Results Consolidated net revenue for the fourth quarter of 2023 was $60.6 million, representing 17.6% and 17.3% reported and constant currency growth, respectively, compared to the fourth quarter of 2022. Consolidated net revenue for the full year 2023 was $216.4 million, representing 19.3% and 19.7% reported and constant currency growth, respectively, compared to the full y
Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 593140. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.pa
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2023 and reaffirmed its 2023 net revenue guidance. Third Quarter 2023 and Nine Months Ended September 30, 2023 Financial Results Consolidated net revenue for the third quarter of 2023 was $52.8 million, representing 14.7% and 14.5% reported and constant currency growth, respectively, compared to the third quarter of 2022. Consolidated net revenue for the nine months ended September 30, 2023 was $155.8 million, representing 20.0% and 20.6% reported and constant currency
Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7, 2023. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (646-904-5544) for international callers, using conference ID: 308457. Live audio of the webcast will be available on the "Investors" section of the company's website at: ir.paragon28.com. The
Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2023 and reaffirmed its 2023 net revenue guidance. Second Quarter 2023 and Six Months Ended June 30, 2023 Financial Results Consolidated net revenue for the second quarter of 2023 was $51.0 million, representing 20.0% and 20.8% reported and constant currency growth, respectively, compared to the second quarter of 2022. Consolidated net revenue for the six months ended June 30, 2023 was $103.0 million, representing 22.9% and 23.9% reported and constant currency growth, respec
8-K - Paragon 28, Inc. (0001531978) (Filer)
8-K - Paragon 28, Inc. (0001531978) (Filer)
144 - Paragon 28, Inc. (0001531978) (Subject)
8-K - Paragon 28, Inc. (0001531978) (Filer)
10-Q - Paragon 28, Inc. (0001531978) (Filer)
8-K - Paragon 28, Inc. (0001531978) (Filer)
10-Q - Paragon 28, Inc. (0001531978) (Filer)
8-K - Paragon 28, Inc. (0001531978) (Filer)
10-Q/A - Paragon 28, Inc. (0001531978) (Filer)
10-K/A - Paragon 28, Inc. (0001531978) (Filer)
SC 13G - Paragon 28, Inc. (0001531978) (Subject)
SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)
SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)
SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)
SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)
SC 13G - Paragon 28, Inc. (0001531978) (Subject)
SC 13G - Paragon 28, Inc. (0001531978) (Subject)
SC 13G - Paragon 28, Inc. (0001531978) (Subject)
SC 13G - Paragon 28, Inc. (0001531978) (Subject)
William Blair initiated coverage of Paragon 28 with a rating of Outperform
Stephens initiated coverage of Paragon 28 with a rating of Overweight and set a new price target of $23.00
B. Riley Securities resumed coverage of Paragon 28 with a rating of Buy and set a new price target of $32.00
B of A Securities reiterated coverage of Paragon 28 with a rating of Buy and set a new price target of $25.00 from $30.00 previously
Canaccord Genuity reiterated coverage of Paragon 28 with a rating of Buy and set a new price target of $23.00 from $25.00 previously
Needham reiterated coverage of Paragon 28 with a rating of Buy and set a new price target of $25.00 from $31.00 previously
JMP Securities initiated coverage of Paragon 28 with a rating of Market Outperform and set a new price target of $30.00
Canaccord Genuity initiated coverage of Paragon 28 with a rating of Buy and set a new price target of $28.00
Piper Sandler initiated coverage of Paragon 28 with a rating of Overweight and set a new price target of $30.00
Needham initiated coverage of Paragon 28 with a rating of Buy and set a new price target of $31.00
Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi
OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since September 2020. Steve's leadership was instrumental in Paragon 28's successful IPO on the NYSE in the fall of 2021. Prior to Paragon 28, Steve held CFO r
Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board's Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president, Urology and Pelvic Health, for Boston Scientific Corporation and is a member of the Boston Scientific Executive Committee. Ms. Scanlon also is a member of the Boston Scientific Global Council for Inclusion, serving as the executive sp
Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of B. Kristine Johnson and Kristina Wright to the Board of Directors, effective December 1, 2021. "I am very pleased to welcome Kris Johnson to our board of directors, as she brings a breadth of med-tech industry leadership and commercial strategy expertise. Kris' expertise in growing medical device businesses will be essential as we expand our commercial infrastructure to be the market leader in the foot and ankle industry," said Albert DaCosta, Founder and CEO of Paragon 28. "We are also excited to welcome Krissy Wright to